EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments

Katherine Appiah, Maria Rizzo, Grammati Sarri, Luis Hernandez

Journal of Comparative Effectiveness Research · 2024

DOI: 10.57264/cer-2023-0140 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Katherine Appiah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cytel, Rotterdam, Netherlands. Hauptthemen laut MEDLINE: Advisory Committees, Biomedical Technology. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The drive to expedite patient access for diseases with high unmet treatment needs has come with an increasing use of single-arm trials (SATs), especially in oncology. However, the lack of control arms in such trials creates challenges to assess and demonstrate comparative efficacy. External control (EC) arms can be used to bridge this gap, with various types of sources available to obtain relevant data.

Objective

To examine the source of ECs in single-arm oncology health technology assessment (HTA) submissions to the National Institute for Health and Care Excellence (NICE) and the Pharmaceutical Benefits Advisory Committee (PBAC) and how this selection was justified by manufacturers and assessed by the respective HTA body.

Methods

Single-arm oncology HTA submission reports published by NICE (England) and PBAC (Australia) from January 2011 to August 2021 were reviewed, with data qualitatively synthesized to identify themes.

Results

Forty-eight oncology submissions using EC arms between 2011 and 2021 were identified, with most submissions encompassing blood and bone marrow cancers (52%). In HTA submissions to NICE and PBAC, the EC arm was typically constructed from a combination of data sources, with the company's justification in data source selection infrequently provided (PBAC [2 out of 19]; NICE [6 out of 29]), although this lack of justification was not heavily criticized by either HTA body.

Conclusion

Although HTA bodies such as NICE and PBAC encourage that EC source justification should be provided in submissions, this review found that this is not typically implemented in practice. Guidance is needed to establish best practices as to how EC selection should be documented in HTA submissions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Advisory CommitteesBiomedical TechnologyHumansEnglandAustraliaTechnology Assessment, BiomedicalCost-Benefit Analysis

Stichwörter der Autor:innen

external controlshealth technology assessmentoncologyreal-world datareal-world evidencesingle-arm trial

Autor:innen und Institutionen

  • Cytel, Rotterdam, Netherlands.
  • Cytel, London, UK.
  • Takeda Pharmaceuticals America, Inc., Lexington, MA, USA.

Zitieren

APA

Appiah, K., Rizzo, M., Sarri, G., & Hernandez, L. (2024). Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2023-0140

Vancouver

Appiah K, Rizzo M, Sarri G, Hernandez L. Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2023-0140

BibTeX
@article{Appiah2024,
  author = {Appiah, Katherine and Rizzo, Maria and Sarri, Grammati and Hernandez, Luis},
  title = {Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2024},
  doi = {10.57264/cer-2023-0140}
}
Kostenlos starten →